HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 274 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.48 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $17,080,856 | +1.1% | 447,143 | -4.5% | 0.01% | +20.0% |
Q2 2023 | $16,890,025 | -14.8% | 468,257 | -9.8% | 0.01% | -16.7% |
Q1 2023 | $19,815,600 | -33.8% | 518,869 | -1.4% | 0.01% | -40.0% |
Q4 2022 | $29,947,000 | +21.4% | 526,322 | -15.7% | 0.01% | +11.1% |
Q3 2022 | $24,674,000 | -10.8% | 624,030 | -0.8% | 0.01% | -10.0% |
Q2 2022 | $27,674,000 | +4.7% | 628,950 | -5.1% | 0.01% | +25.0% |
Q1 2022 | $26,425,000 | +4.1% | 662,638 | +5.0% | 0.01% | +14.3% |
Q4 2021 | $25,376,000 | +6.3% | 631,127 | +7.6% | 0.01% | -12.5% |
Q3 2021 | $23,865,000 | -8.1% | 586,665 | +2.6% | 0.01% | 0.0% |
Q2 2021 | $25,975,000 | +4.9% | 572,006 | -3.7% | 0.01% | 0.0% |
Q1 2021 | $24,772,000 | -13.3% | 594,212 | -11.2% | 0.01% | -20.0% |
Q4 2020 | $28,579,000 | +148.9% | 669,143 | +53.2% | 0.01% | +100.0% |
Q3 2020 | $11,481,000 | -2.4% | 436,864 | -0.4% | 0.01% | 0.0% |
Q2 2020 | $11,759,000 | +59.9% | 438,590 | +7.3% | 0.01% | +25.0% |
Q1 2020 | $7,353,000 | +5.2% | 408,757 | +3.7% | 0.00% | +33.3% |
Q4 2019 | $6,990,000 | +11.0% | 394,239 | -2.9% | 0.00% | 0.0% |
Q3 2019 | $6,299,000 | -9.8% | 406,062 | -0.1% | 0.00% | 0.0% |
Q2 2019 | $6,982,000 | +74.4% | 406,387 | +63.4% | 0.00% | +50.0% |
Q1 2019 | $4,004,000 | +9.2% | 248,685 | -0.8% | 0.00% | 0.0% |
Q4 2018 | $3,668,000 | -12.7% | 250,724 | +8.5% | 0.00% | +100.0% |
Q3 2018 | $4,200,000 | +70.0% | 231,166 | +57.8% | 0.00% | 0.0% |
Q2 2018 | $2,471,000 | -13.8% | 146,464 | +0.1% | 0.00% | 0.0% |
Q1 2018 | $2,867,000 | +32.2% | 146,367 | +36.7% | 0.00% | 0.0% |
Q4 2017 | $2,168,000 | -7.6% | 107,051 | -20.7% | 0.00% | 0.0% |
Q3 2017 | $2,346,000 | +34.4% | 134,968 | -0.8% | 0.00% | 0.0% |
Q2 2017 | $1,745,000 | -73.1% | 136,072 | -72.8% | 0.00% | -66.7% |
Q1 2017 | $6,488,000 | +22.7% | 500,613 | -6.4% | 0.00% | 0.0% |
Q4 2016 | $5,286,000 | +339.4% | 535,003 | +670.7% | 0.00% | +200.0% |
Q4 2015 | $1,203,000 | +43.6% | 69,422 | +11.3% | 0.00% | 0.0% |
Q3 2015 | $838,000 | -73.0% | 62,351 | -54.7% | 0.00% | -50.0% |
Q2 2015 | $3,106,000 | +63.4% | 137,595 | +3.4% | 0.00% | +100.0% |
Q1 2015 | $1,901,000 | +1745.6% | 133,096 | +1146.8% | 0.00% | – |
Q4 2014 | $103,000 | +186.1% | 10,675 | +170.6% | 0.00% | – |
Q3 2014 | $36,000 | +2.9% | 3,945 | +12.9% | 0.00% | – |
Q2 2014 | $35,000 | -32.7% | 3,495 | -13.7% | 0.00% | – |
Q1 2014 | $52,000 | -14.8% | 4,050 | -1.5% | 0.00% | – |
Q4 2013 | $61,000 | -14.1% | 4,110 | -36.5% | 0.00% | – |
Q3 2013 | $71,000 | +42.0% | 6,468 | +3.6% | 0.00% | – |
Q2 2013 | $50,000 | – | 6,243 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Security, LLC | 14,092,771 | $256,066,000 | 16.64% |
BB BIOTECH AG | 8,247,860 | $149,864,000 | 3.97% |
MSD Partners, L.P. | 2,245,000 | $40,792,000 | 3.07% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 428,633 | $5,969,000 | 2.84% |
First Light Asset Management, LLC | 885,523 | $16,090,000 | 2.60% |
SNYDER CAPITAL MANAGEMENT L P | 2,387,350 | $43,378,000 | 1.93% |
Sterling Global Strategies LLC | 22,000 | $400,000 | 1.74% |
Taylor Wealth Management Partners | 221,380 | $4,022,000 | 1.71% |
IRIDIAN ASSET MANAGEMENT LLC/CT | 9,228,399 | $167,680,000 | 1.68% |
DOHENY ASSET MANAGEMENT /CA | 124,393 | $2,260,000 | 1.18% |